title: Stereotypic progressions in psychotic behavior.
abstract: Dopamine receptor supersensitivity (DARSS) often is invoked as a mechanism possibly underlying disordered thought processes and agitation states in psychiatric disorders. This review is focused on identified means for producing DARSS and associating the role of other monoaminergic systems in modulating DARSS. Dopamine (DA) receptors, experimentally, are prone to become supersensitive and to thus elicit abnormal behaviors when coupled with DA or a receptor agonist. In intact (control) rats repeated DA D₁ agonist treatments fail to sensitize D₁ receptors, while repeated D₂ agonist treatments sensitize D₂ receptors. D₂ RSS is attenuated by a lesion with DSP-4 (N-(2-chlorethyl)-N-ethyl-2-bromobenzylamine) in early postnatal ontogeny, indicating that noradrenergic nerves have a permissive effect on D₂ DARSS. However, if DSP-4 is co-administered with 5,7-dihydroxytryptamine to destroy serotonin (5-HT) nerves, then D₂ RSS is restored. In rats treated early in postnatal ontogeny with the neurotoxin 6-hydroxydopamine to largely destroy DA innervation of striatum, both repeated D₁ and D₂ agonists sensitize D₁ receptors. 5-HT nerves appear to have a permissive effect on D₁ DARSS, as a 5-HT lesion reduces the otherwise enhanced effect of a D₁ agonist. The series of findings demonstrate that DARSS is able to be produced by repeated agonist treatments, albeit under different circumstances. The involvement of other neuronal phenotypes as modulators of DARSS provides the potential for targeting a variety of sites in the aim to prevent or attenuate DARSS. This therapeutic potential broadens the realm of approaches toward treating psychiatric disorders.
authors.affiliation: Department of Pharmacology, Quillen College of Medicine, East Tennessee State University, PO Box 70577, Johnson City, TN 37614, USA. kostrzew@etsu.edu
authors.forename: Richard M
authors.initials: RM
authors.lastname: Kostrzewa
authors.forename: John P
authors.initials: JP
authors.lastname: Kostrzewa
authors.forename: Rose Anna
authors.initials: RA
authors.lastname: Kostrzewa
authors.forename: Florence P
authors.initials: FP
authors.lastname: Kostrzewa
authors.forename: Ryszard
authors.initials: R
authors.lastname: Brus
authors.forename: Przemyslaw
authors.initials: P
authors.lastname: Nowak
mesh_terms: D000818:Animals; D018450:Disease Progression; D018491:Dopamine Agonists / Q000378:metabolism; D006801:Humans; D011618:Psychotic Disorders / Q000175:diagnosis* / Q000209:etiology / Q000523:psychology*; D011954:Receptors, Dopamine / Q000378:metabolism; D013239:Stereotyped Behavior / Q000502:physiology*
chemical_list: D018491:Dopamine Agonists; D011954:Receptors, Dopamine
references.citation: Pharmacol Biochem Behav. 2000 Sep;67(1):11-5
references.pmid: 11113478
references.citation: J Neurochem. 1994 Oct;63(4):1282-90
references.pmid: 7931280
references.citation: Pharmacol Biochem Behav. 1993 Jul;45(3):737-40
references.pmid: 8332633
references.citation: Am J Drug Alcohol Abuse. 2009;35(3):161-77
references.pmid: 19462300
references.citation: J Pharmacol Exp Ther. 1997 Jan;280(1):268-76
references.pmid: 8996206
references.citation: Neurotox Res. 2003;5(1-2):111-8
references.pmid: 12832226
references.citation: Brain Res Dev Brain Res. 1993 Dec 17;76(2):233-8
references.pmid: 8149589
references.citation: Med J Aust. 2009 Feb 16;190(S4):S22-5
references.pmid: 19220169
references.citation: Neurotox Res. 2007 Jan;11(1):41-50
references.pmid: 17449447
references.citation: J Pharmacol Exp Ther. 1987 Jan;240(1):167-76
references.pmid: 3100767
references.citation: J Neurosci. 1989 Jan;9(1):125-33
references.pmid: 2521511
references.citation: Life Sci. 1991;48(26):PL129
references.pmid: 1675416
references.citation: Neurotox Res. 2004;6(4):317-25
references.pmid: 15545015
references.citation: Pharmacol Biochem Behav. 1993 Feb;44(2):487-9
references.pmid: 8095344
references.citation: Pharmacol Biochem Behav. 1995 Apr;50(4):649-53
references.pmid: 7617714
references.citation: Psychopharmacology (Berl). 1995 Jun;119(4):466-73
references.pmid: 7480527
references.citation: J Neurochem. 1998 Mar;70(3):889-98
references.pmid: 9489707
references.citation: Pharmacol Biochem Behav. 2004 May;78(1):47-56
references.pmid: 15159133
references.citation: Pharmacol Rep. 2009 Mar-Apr;61(2):311-8
references.pmid: 19443944
references.citation: Neurotox Res. 2007 Feb;11(2):131-44
references.pmid: 17449455
references.citation: Life Sci. 1983 Dec 19;33(25):2479-82
references.pmid: 6227782
references.citation: Pharmacol Biochem Behav. 1991 Jul;39(3):677-82
references.pmid: 1686103
references.citation: J Pharmacol Exp Ther. 1992 Jun;261(3):1000-7
references.pmid: 1602367
references.citation: J Pharmacol Exp Ther. 1985 Nov;235(2):287-95
references.pmid: 3932640
references.citation: Pharmacol Biochem Behav. 1992 Mar;41(3):621-3
references.pmid: 1584843
references.citation: Neurotox Res. 2004;6(6):457-62
references.pmid: 15639779
references.citation: Brain Res Dev Brain Res. 1993 Nov 19;76(1):59-65
references.pmid: 8306431
references.citation: Neurotox Res. 2008 Oct;14(2-3):121-8
references.pmid: 19073420
references.citation: Adv Exp Med Biol. 1988;235:159-67
references.pmid: 2976249
references.citation: Amino Acids. 2005 Mar;28(2):157-64
references.pmid: 15750845
references.citation: Pharmacol Biochem Behav. 1991 Jun;39(2):517-9
references.pmid: 1682952
references.citation: Pol J Pharmacol. 2001 Jul-Aug;53(4):319-29
references.pmid: 11990078
references.citation: J Pharmacol Exp Ther. 1985 Aug;234(2):447-55
references.pmid: 3926987
references.citation: Eur J Pharmacol. 1993 Aug 3;239(1-3):183-7
references.pmid: 7901028
references.citation: Neurotox Res. 2003;5(5):329-38
references.pmid: 14715452
references.citation: J Pharmacol Exp Ther. 1984 Nov;231(2):343-54
references.pmid: 6149306
references.citation: J Pharmacol Exp Ther. 1994 Jan;268(1):231-7
references.pmid: 8301563
references.citation: Neurosci Biobehav Rev. 1995 Spring;19(1):1-17
references.pmid: 7770190
references.citation: Brain Res Bull. 1994;34(2):161-7
references.pmid: 7913871
references.citation: Brain Res Dev Brain Res. 1993 Nov 19;76(1):87-93
references.pmid: 8306435
references.citation: Pharmacol Biochem Behav. 1991 Jan;38(1):215-8
references.pmid: 1901995
references.citation: Eur J Pharmacol. 1991 Dec 17;209(3):157-61
references.pmid: 1686767
references.citation: Synapse. 1987;1(2):133-52
references.pmid: 2905529
references.citation: Neurotox Res. 2008 Oct;14(2-3):79-96
references.pmid: 19073416
references.citation: Eur J Pharmacol. 1991 Oct 2;203(1):115-20
references.pmid: 1839147
references.citation: Pharmacol Biochem Behav. 2006 May;84(1):3-7
references.pmid: 16675001